Evidence map›Paper›PMID 27991924›Full record

ArticleOncogene2017

Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche.

K Shahriari, F Shen, A Worrede-Mahdi, Q Liu, Y Gong, F U Garcia, A Fatatis

Abstract read
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Differential Effects of a First-in-Class IKKCalcified tissue international · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

K ShahriariDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA.
F ShenDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA.
A Worrede-MahdiDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA.
Q LiuDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA.
Y GongDepartment of Pathology and Laboratory Medicine, Drexel University College of Medicine, Philadelphia, PA, USA.
F U GarciaDepartment of Pathology and Laboratory Medicine, Drexel University College of Medicine, Philadelphia, PA, USA.
A FatatisDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA.
Drexel University · USEastern Regional Medical Center · US

Funding

IL-1b-mediated tumor-stromal interaction and prostate cancer cell cooperation in the bone metastatic nicheF30CA192896 · NCI · DREXEL UNIVERSITY · PI SHAHRIARI, KRISTINA · 2015 to 2018
$184k
NCI NIH HHS F30 CA192896
6 · The paper itself

Abstract

The growth of disseminated tumor cells into metastatic lesions depends on the establishment of a favorable microenvironment in the stroma of the target organs. Here we show that mice treated with anakinra, an antagonist of the interleukin (IL)-1β receptor (IL-1R), or harboring a targeted deletion of IL-1R are significantly less prone to develop bone tumors when inoculated in the arterial circulation with human prostate cancer (PCa) cells expressing IL-1β. Interestingly, human mesenchymal stem cells exposed in vitro to medium conditioned by IL-1β-expressing cancer cells responded by upregulating S100A4, a marker of cancer-associated fibroblasts (CAFs), and this effect was blocked by anakinra. Analogously, the stroma adjacent to skeletal metastases generated in mice by IL-1β-expressing cancer cells showed a dramatic increase in S100A4, COX-2 and the alteration of 30 tumor-related genes as measured by Nanostring analysis. These effects were not observed in the stroma associated with the rare and much smaller metastases generated by the same cells in IL-1R knockout animals, confirming that tumor-secreted IL-1β generates skeletal CAFs and conditions the surrounding bone microenvironment. In skeletal lesions from patients with metastatic PCa, histological and molecular analyses revealed that IL-1β is highly expressed in cancer cells in which the androgen receptor (AR) is not detected (AR-), whereas this cytokine is uniformly absent in the AR-positive (AR+) metastatic cells. The stroma conditioned by IL-1β-expressing cancer cells served as a supportive niche also for coexisting IL-1β-lacking cancer cells, which are otherwise unable to generate tumors after independently seeding the skeleton of mice. This niche is established very early following tumor seeding and hints to a role of IL-1β in promoting early colonization of PCa at the skeletal level.

Indexed as

Cell CommunicationTumor MicroenvironmentAnimalsBiomarkersBone NeoplasmsCell Line, TumorCell ProliferationDisease Models, AnimalGene ExpressionHeterograftsHumansInterleukin-1betaMaleMesenchymal Stem CellsMiceNeoplasm MetastasisBiomarkersInterleukin-1betaReceptors, Androgen

Identifiers

PMID27991924
PMCPMC5436952
OpenAlexW2562902715

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.